Previous 10 | Next 10 |
home / stock / aezs:cc / aezs:cc news
K-Bro Linen Inc. (KBL:CA) is expected to report $0.57 for Q3 2023 Yellow Pages Limited (Y:CA) is expected to report for Q3 2023 Ascot Resources Ltd. (AOT:CA) is expected to report for Q3 2023 Park Lawn Corporation (PLC:CA) is expected to report $0.27 for Q3 2023 Hut 8 Mining Corp....
Baytex Energy Corp. (BTE:CA) is expected to report $0.23 for Q3 2023 Logistec Corporation Class A Common Shares (LGT.A:CA) is expected to report for Q1 2024 ARC Resources Ltd. (ARX:CA) is expected to report $0.48 for Q3 2023 Lightspeed Commerce Inc. Subordinate Voting Shares (LSPD:CA)...
AEterna Zentaris Inc. (AEZS:CA) is expected to report $-0.82 for Q3 2023
– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25 th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the &...
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,...
2023-09-02 20:00:00 ET AEterna Zentaris is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the Toronto Stock Exchange or TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to...
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025 Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) ...
Highlights progress, recent developments and upcoming key milestones C ompany c ontinu es to build growing body of data across pipeline , a dvancing towards first in human studies S trong financial position with cash projected to fund op...
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS:CC Stock Symbol:
TSXC Market:
TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (" Aeterna ") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approvin...
- Company confirms successful completion of enrollment in the pivotal DETECT Phase 3 trial - Company ended the year with $34.0 million in cash, expected to fund operations through 2024 and into 2025 - All-stock merger of equals transaction with Ceapro, Inc. expected to close i...
TORONTO and EDMONTON, Alberta, March 12, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“ Aeterna ”) and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“ Ceapro ”) are pleased to announce that securityholders of both biopharmaceutical devel...